findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. Feb 240–247
Brückmann H see Frodl T
Bryant RA. Acute stress disorder as a predictor of posttraumatic stress disorder: a systematic review. Feb 233–239
Buckley PF see Kane JM
Bühner M see Hamann J
Burdick KE see Gilbert AM
Bush AI see Berk M
Bussbach JIV see Soeteman DI
Bystritsky AM see Shiovitz TM; Stein MB
Calabrese JR see Brooks JO III; Gao K; Kemp DE; Muzina DJ
Campbell EC see Carson RJ
Campbell-Sills L see Stein MB
Capello F see Moscardino U
Carballo JJ see Dervic K
Carlson BX see Weisler RH
Carson WH see Marcus RN
Carson WH see Van Dorn RA
Carson WH see Van Dorn RA
Carver C see Gordon AM
Carver C see Gordon AM
Carter T see Compton MT
Cascorbi I see Athanasiou MC
Casillas EM see Bourgeois JA
Cassella JV see Allen MH
Castellvi P see Diez-Quevedo C
CATIE Investigators see Caroff SN
Cattaneo A see Mondelli V
Cavallo DA see Liu TC
Cerimele JM. Integrated medical care for patients with bipolar disorder: will he be the principal physician? [letter]. May 723–724
Chakos MW see Caroff SN
Chan P see Calabrese JR
Chan PK see Muzina DJ
Chan RCK see Zhang W-F
Chandler K see Van Dorn RA
Chang C-J see Chan H-Y
Chang C-L see Koo C-J
Chang KD see Axelos DA
Chang TL see Desseilles M
Chaplin W see Berlin HA
Chappell PB see Sachs GS
Chamley DS see Bonne O; Murrough JW
Chatterjee S seeNuevo R
Chelminski I see Zimmerman M
Chen C-C see Koo C-J
Chen C-N see Polo AJ
Chen J-Y see Bai YM
Chen TT see Bai YM
Chen WJ see Koo C-J
Chen Y see Meltzer HY
Chen Y-F see Khan NA
Chen Y-Y, Yip PSF. Suicide sex ratios after the inception of charcoal-burning suicide in Taiwan and Hong Kong [letter]. Apr 566–567
Cheng Q, Fu K-w, Yip PSF. Comparative study of online suicide-related information in Chinese and English. Mar 313–319
Dinstein Y see Nacash N
Diplich D see Hamann J
Dommeregues M see Gerardin P
Donoho DA see Lawson EA
Dording CM see Desseilles M
do Rosário MC see Torres AR
Dosil JA see Olsson M
Doty L see George DT
Dowd SM see Wall CA
Doyle AE see Biederman J
Driessen M see Terfek k
Drus B see Compton MT; Pagura J
Dunlop BW see Rakofsky JF
Dunn AL see Trivedi MH
Dunner DL. Review of Mrazek DA: Psychiatric Pharmacogenomics. May 727
Dupuy JM see Sachs GS
Earnest CP see Trivedi MH
Edelen MO see Yen S
Edlund NJ see Fortney JC
Eickhoff M see Gaebel W
Eikenboom P see Oudega ML
Eliot JD see Archambeau OG
Elizaguirre E see Lertzuddi U
Ellingrod VL see Calarge CA
Elliott BL. Does combat trauma cause a majority of PTSD symptoms in combat veterans? [letter with reply] May 724–725
Ellis SP see Sublette ME
Emerenini CA see Andreucci C
Empiana J-P see Nabi H
Emslie GJ see Vitiello B; Wall CA
Erictick J see Leon AC
Ernst A see Buenger K
Ernst E see Lee MS
Eronen M see Tchoukhine E
Eser D see Baghai TC
Esterberg ML see Compton MT
Eudicone JM see Weisler RH
EUFRST Study Group see Volavka J
Evans SJW see Petersen I
Evins AE seeiovieno N
Exner Cee Timpano KR
Falisass B see Corrubel E
Fang Y see Gao K
Fani N see Bradley B
Faraoe SV see Biederman J; Walmansky JG
Farber SB see Swardfager W
Farmer A see Uher R
Fauerbach JA see Gould NF
Fava GA see Grandi S
Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and eszopiclom treatment: a randomized controlled trial. July 914–928
Fava M, Shefton RK, Zajecka JM. Evidence for the use of l-methylfolate combined with antidepressants in MDD. Aug e25
Fava M see Chen JA; Desseilles M; Posternak MA;
Tedeschini E; Zisook S
Fazel S see Jones RM
Feaganes JR see Shemesh E
Feild D see Allen MH
Fein E see Gao K
Feingold A see Remington G
Fernando SC see Terfehr K
Ferraro YA see Torres AR
Ferrucio L see Vogelzangs N
Fedorowicz JG see Leon AC
Figen VP see Roldan CU
Finnding BL see Axelsson DA; Frazier TW; Marcus RN
Fine T see Calabrese JR
First MB see Wakefield JC
Fishman SM. Strategies for selecting treatment and mitigating risk in patients with chronic pain. Jan e02
Fleischacker WW see Volavka J
Flood P see Rodriguez CI
Foa EB see Nacash N
Fong P see Carpenter DJ
Fontenelle LF see Torres AR
Fortney JC see Mittal D
Fossom L see Laughren TG
Foster JA see Lokoju S
Fostick L see Nacash N
Fousias G see Agid O
Fraguas D see Nuevo R
Franczy SM see Yung AR
Francis A see Gurera RJ
Frasure-Smith N see Leparencé F
Freeman MP. Antidepressant medication treatment during pregnancy: prevalence of use, clinical implications, and alternatives. July 977–978
Freeman MP. Biopsychosocial vulnerabilities in women [introduction]. Nov 1529–1530
Freeman MP, Rapaport MH. Omega-3 fatty acids and depression: from cellular mechanisms to clinical care [ASCP Corner]. Feb 258–259
Freeman MP see Desseilles M; Gelenberg AJ
Freudeneich D see Goft DC
Frey BN see Kapczinski F; Lokoju S
Fried R see Biederman J
Friedman SH, Resnick PJ. Child murder and mental illness in parents: implications for psychiatrists [commentary]. May 587–588
Frisch U see Wiz-Justice A
Fristad MA see Axelsson DA; Frazier TW
Frolich U see Hausner L
Frukt S see Gurera R, B
Fruhe BC see Archambeau OG
Fruhe C see Crisanti AS
Fu K-W see Cheng Q
Fujita H see Watanabe N
Furukawa TA see Watanabe N
Gaede W, Riesbeck M, Reply to Suzuki T: Risks of intermittent antipsychotic treatment in schizophrenia [letter]. Jan 114–115
Galea S see Calabrese JR
Gallavich IIC see Derry K
Galin A see Gerardin P
Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, Kane JM. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? Dec 1691–1696
Gallipoli S see Khan A
Galper DI see Trivedi MH
Galyaner II see Katz C
Ganocy SJ see Calabrese JR, Gao K, Muzina DJ
Ganoczy D see Smith EG
Gao K, Kemp DC, Calabrese JR. Reply to Citrome L. Likelihood to be helped or harmed can assist in clinical decision-making [letter]. Feb 262
Kane JM. Addressing side effects from antipsychotic treatment in schizophrenia. Feb e07
Kane JM. Improving treatment adherence in patients with schizophrenia. Sept e28
Kane JM. Larusadone: a clinical overview. Suppl 1, 24–28
Kane JM. Performance improvement CME: schizoaffective disorder. July e23
Kane JM. Recent advances in treatments for schizophrenia [introduction]. Suppl 1, 3
Kane JM. Transitioning from acute to long-term treatment in schizophrenia. Mar e30
Kane JM, Correll CU. Performance improvement CME: managing schizophrenia. Oct e31
Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A. Panagides J. Randomized placebo-controlled trial of asapenae for the prevention of relapse of schizophrenia after long-term treatment. Mar 349–355
Kane JM, Potkin SG, Daniel DG, Buckley PF. Double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. Feb 194–204
Kane JM. see Athanasiou MC; Correll CU; Gallego JA; Manu P
Kapur N see Oude Voshaar RC
Kapur S see Agid O; Remington G; Sparshatt A
Karayal ON, Anway SD, Batzar E, Vanderburg DG. Bipolar disorder. July e22
Kasuba B see Sachs GS
Kawahara C see Watanabe N
Katz LY see Pagura J
Katz F see Berk M
Katz LF see Pagura J
Kaur I see Bourgeois JA
Kavamura C see Watanabe N
Keefe RSE see Caroff SN
Kegeles LS see Rodriguez CI
Kemp DE, Johnson E, Wang WW, Tohen M, Calabrese JR. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. Sept 1236–1241
Kemp DE see Gao K; Muzina DJ
Kendall B see Vitiello B
Keshaviah A see Timpano KR
Ketter TA. Strategies for the early recognition of bipolar disorder. July e22
Ketter TA see Brooks JO III
Khaliﬁe S see Muzina DJ
Khalifa H-MK see Salvatore P
Khan A, Cutler AJ, Kajdaz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR. Randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotoninergic agent for the treatment of major depressive disorder. Apr 441–447
Khan A see Weisler RH
Khan BK see Woolley JD
Kidolesi Y see Signorovitch J
Kim JB see Woo J-M
Kim J-F see Lee MS
Kim JJ see Soeteman DI
Kim NF see Rottmann BM
Kim YS see Hong HJ
Kirmayer L see Milan B
Kiss A see Swardfager W
Kissling W see HamANN J
Kivimäki M see Nabi H
Kleban M. Review of Grant JE, Potenza MN (eds): Young Adult Mental Health. June 875
Klibanski A see Lawson EA
Klimke V see Laughren TP
Klimke A see Gaebel W
Klingenberg S see Gaebel W
Klöppel S see Bauml RA
Klingenberg S see Laughren TP
Klipanski JA see Paulzen M
Koiroogeve KE see Bergvik G
Köpcke W see Gaebel W
Kopf D see Hummel J
Koran LM see Berlin HA
Kotrav V see Ruggiero C
Koutsouleris N see Frodl T
Kraemer HC. Another point of view: superiority, noninferiority, and the role of active comparators [commentary]. Oct 1350–1352
Kratovil CT see Correll CU

© COPYRIGHT 2011 PHYSICIANS POSTGRADUATE PRESS, INC. © COPYRIGHT 2011 PHYSICIANS POSTGRADUATE PRESS, INC.
Roth T see Fava M; Surman CBH
Rottman BM, Kim NS, Ahn W-k, Sanislow CA. Can personality disorder experts recognize DSM-IV personality disorders from five-factor model descriptions of patient cases? May 630–639
Roy M see Roy A
Roy-Byrne PP see Stein MB
Ruan WS see Pickering RP
Rubinstein D see Shemesh E
Ruf B see Saricicek A
Rupprecht R see Baghai TC
Rush AJ see Harding KJK; Zisook S
Ryan ND see Axelsson DA; Frazier TW; Vitiello B
Saba S see Nabi H
Sachdev PS see Gurerra RJ
Sachs GS, Dupuy JM, Wittmann CW. Pharmacologic treatment of bipolar disorder. May 704–715
Sadhu JM, Beresin EV. Review of Parents H: Handling Children's Aggression Constructively: Toward Taming Human Destructiveness. Oct 1432
Saha TD see Pickering RP
Sajeev G see Agid O
Saleem M see Saricicek A
Saltwick BA see Athanasiou MC
Salz T see Caroff SN
Salvai FR see Crisantis A
Sampson SM see Wall CA
Sanacora G see Saricicek A
Sanchez-Toledo JP see Salvatore P
Sanislow CA see Rottman BM; Yen S
Sartorius A see Hausner L
Saski M see Watanabe N
Sauer H see Gaebel W
Sauer N see Löwe B
Schaefer K see Fava M
Schapkaitz I see Berk M
Scheibitz M see Hamann J
Scheitels P see Oudega ML
Schneider A see Bourgeois JA
Schnyder U, Müller J, Maercker A, Wittmann L. Brief ecletic psychotherapy for PTSD: a randomized controlled trial [letter]. Apr 564–566
 Schoepf V see Frodl T
Schüle C see Baghai TC
Schulz LC see Zanarini MC
Schwartz JH see Sachs GS
Scrimin S see Moscardino U
Seeman P see Remington G
Segalás C see Labad J
Seiran AL see Bourgeois JA
Serrano MB see Calabrese JR; Muzina DJ
Serrano-Blanco A see Usall J
Sevy SM see Gallego JA
Shammi C see Remington G
Shapira NA see Berlin HA
Sharma B see Fan X
Shaya Y see Gilbert AM
Shea MT see Yen S
Shear MK see Zisook S
Sheehan DV see Fava M
Shelton JS. Cosmetics count [Publisher's Note]. Sept 1165
Shelton JS. JCP 2011: our world keeps improving [Publisher's Note]. June 736
Shelton JS. NCDEU Festschrift—celebrating 50 years [Publisher's Note]. May 579
Shelton RC, Trivedi MH. Challenges and algorithm-guided treatment in major depressive disorder. Apr e14
Shelton RC, Trivedi MH. Moderators of antidepressant response in major depression. Oct e32
Shelton RC, Trivedi MH. Performance improvement CME: algorithms and EMRs in depression. Sept e29
Shelton RC, Trivedi MH. Using algorithms and computerized decision support systems to treat major depression. Dec e36
Shelton RC, Trivedi MH. Using moderator-based algorithms and electronic medical records to achieve optimal outcomes in depression. July e24
Shelton RC see Barbee JG; Fava M; Nierenberg AA

Teboiu E. Keeping ‘em honest: the current crisis of confidence in antidepressants [letter with reply]. July 1015

Tedesci E, Fava M, Papakostas GI. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks’ duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio–based approach. Jan 98–103


Tedesci E see Iovieno N; Levkovitz Y

Teigel SJ see Bueger K

Temple RJ see Laughren TP

Terao T. Can pindolol really enhance antidepressant effect? [letter with reply] Nov 1558

Tereninov V see Tchoukhine E


Terman M see Wirz-Justice A

Thampar A see Yang AR

Thase ME. Role of neurobiologic processes in symptoms of depression. Feb e08

Thase ME. Treatment-resistant depression: prevalence, risk factors, and treatment strategies. May e18

Thase ME see Brooks JO III; Carpenter DJ; Cristancho P; Swartz HA

Thein K see Cohen-Mansfield J

Thewissen V see Lataster J

Thompson AD see Yung AR

Thomson PM see Barbee JG

Thompson TR see Barbee JG

Thuinissen M see Soeteman DI


Tohen M see Kemp DE; Salvatore P


Tordjman S see Gerard P

Torres AR, Ramos-Cerqueira AT, Ferrão YA, Fontenelle LF, de los Rosario MC, Miguel EC. Suicidality in obsessive-compulsive disorder: prevalence and relation to symptom dimensions and comorbid conditions. Jan 17–26

Tossani E see Grandi S

Tran OV see Weisler RH

Trial 144 Study Investigators see Weisler RH

Trifflemen EG see Grisanti AS

Trivedi MH, Greer TL, Church TS, Carmody TJ, Grannemann BD, Galper DJ, Dunn AL, Earnest CP, Sanderajan P, Henley SS, Blair SN. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. May 677–684


Trivedi MH see Harding KJ; Nierenberg AA; Shelton RC; Weisler RH; Zisook S

Trollor JC see Gurrera RJ

Tsai S-Y see Kuo C-J

Tsoul S see Periogianiss V

Tsuang J see Makhinson H

Turecki G see Lespérance F

Turner JB see Comer JS

Tuzar D see Nasacsh N


Fontenelle LF, do Rosário MC, Miguel EC.


van Balkom AJLM see Lamers F; Wiersma JE

van der Beek R see Soeteman DI

Vieta E see Cruz N; Frye MA; González-Pinto A; Kapczinski F; Salvador P


Vivek S. Review of Leigh H: Genes, Memes, Culture, and Mental Illness: Toward an Integrative Model. Dec 1699

Vogelzangs N, Beekman ATF, Boelhouwer IJ, Bandinelli S, Milaneschi Y, Ferrucci L, Penninx BWJH. Metabolic depression: a chronic depressive subtype? Findings from the InCHIANTI study of older persons. May 598–604


von Schacky C see Baghai TC

von Wilmsdorf M see Gaaebel W

Vythilingam M see Bonne O

Wagner KD. Controversial issues in child psychiatry [introduction]. June 835

Wagner KD. Impact of mood disorders [introduction]. Mar 376–377

Wagner KD. Potpourri of timely topics [introduction]. Sept 1248–1249

Wagner KD see McIntyre RS; Vitiello B

Wakefield JC, First MB. Treatment outcome for bereavement-excluded depression: results of the study by Corruble et al are not what they seem [letter with reply]. Aug 1155

Walker EF see Compton MT

Walker JR see Kinley DJ


van Elst LT, Klöppel S, Rauer S. Voltage-gated potassium channel/LGI1 antibody–associated encephalopathy may cause brief psychotic disorder [letter]. May 722–723

van Exel E see Ouodega ML

Van Meter AR, Moreira ALR, Youngstrom EA. Meta-analysis of epidemiologic studies of pediatric bipolar disorder. Sept 1250–1256

van Oppen P see Lamers F; Wiersma JE

van Os J see Lataster J

van Schaik DIF see Wiersma JE


Varallo-Bedarada G see Baghai TC

Vázquez G see Frye MA

Velamoor VR see Gurrera RJ

Verdes E see Nuevo R

Verheul R see Soeteman DI

Vita E see Cruz N; Frye MA; González-Pinto A; Kapczinski F; Salvador P


Vivek S. Review of Leigh H: Genes, Memes, Culture, and Mental Illness: Toward an Integrative Model. Dec 1699

Vogelzangs N, Beekman ATF, Boelhouwer IJ, Bandinelli S, Milaneschi Y, Ferrucci L, Penninx BWJH. Metabolic depression: a chronic depressive subtype? Findings from the InCHIANTI study of older persons. May 598–604


von Schacky C see Baghai TC

von Wilmsdorf M see Gaaebel W

Vythilingam M see Bonne O

Wagner KD. Controversial issues in child psychiatry [introduction]. June 835

Wagner KD. Impact of mood disorders [introduction]. Mar 376–377

Wagner KD. Potpourri of timely topics [introduction]. Sept 1248–1249

Wagner KD see McIntyre RS; Vitiello B

Wakefield JC, First MB. Treatment outcome for bereavement-excluded depression: results of the study by Corruble et al are not what they seem [letter with reply]. Aug 1155

Walker EF see Compton MT

Walker JR see Kinley DJ
